Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Gains from Sales and Divestitures: 2016-2024

Historic Gains from Sales and Divestitures for Intellia Therapeutics (NTLA) over the last 9 years, with Dec 2024 value amounting to $1.4 million.

  • Intellia Therapeutics' Gains from Sales and Divestitures rose 35.02% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year increase of 35.02%. This contributed to the annual value of $1.4 million for FY2024, which is 111.75% up from last year.
  • Latest data reveals that Intellia Therapeutics reported Gains from Sales and Divestitures of $1.4 million as of FY2024, which was up 111.75% from $677,055 recorded in FY2023.
  • In the past 5 years, Intellia Therapeutics' Gains from Sales and Divestitures ranged from a high of $1.4 million in FY2024 and a low of $82,829 during FY2020.
  • In the last 3 years, Intellia Therapeutics' Gains from Sales and Divestitures had a median value of $677,055 in 2023 and averaged $752,799.
  • Data for Intellia Therapeutics' Gains from Sales and Divestitures shows a peak YoY skyrocketed of 358.48% (in 2023) over the last 5 years.
  • Yearly analysis of 5 years shows Intellia Therapeutics' Gains from Sales and Divestitures stood at $82,829 in 2020, then soared by 44.53% to $119,715 in 2021, then rose by 23.35% to $147,674 in 2022, then surged by 358.48% to $677,055 in 2023, then skyrocketed by 111.75% to $1.4 million in 2024.